InsidersTradesSigma
Total declarations
Companies
▲ Purchases (2 ops.)
▼ Sales (1 ops.)
Insider track record
ExecutiveDisclosed buys
2
Disclosed sells
1
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Explore the full record of transactions filed by Schulman Amy W, Director. Insider active across 5 companies, notably Elevance Health, Inc.. Aggregated, 13 disclosures have been logged. Split: 2 buys · 1 sell. Total volume traded: €33k. History available since 13 December 2021. The latest transaction was disclosed on 20 May 2026 (Attribution). Regulator: SEC (Form 4). All data is accessible without signup.
Companies and markets linked to Schulman Amy W
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations13 total
838 shares0Common StockSEC:0001178670-26-000041:0
563 shares0Common StockSEC:0001438226-26-000009:0
11,250 shares@ US$70.200.0018% mcap100.0% of flowCommon StockSEC:0001178670-26-000017:0
26 shares@ US$287.500.0000% mcap50.0% of flowCommon StockSEC:0001438226-26-000007:0
218 shares0Common StockSEC:0001438226-26-000005:0
775 shares0Common StockSEC:0001735276-25-000061:0
8,550 shares@ US$1.1654100.0% of flowCommon StockSEC:0000950170-25-040466:0
Canonical exit: 11 Jun 2025 (T+90)
2,750 shares@ US$131.218.5% of flowCommon StockSEC:0001735276-25-000037:0
8,500 shares@ US$131.2126.7% of flowCommon StockSEC:0001735276-24-000072:0
30,000 shares@ US$66.8347.6% of flowCommon StockSEC:0001735276-24-000058:0
136 shares0Common StockSEC:0001735276-23-000019:0
10,091 shares@ US$2.0225.2% of flowCommon StockSEC:0001209191-21-071110:0
1,850 shares@ US$10.8824.8% of flowCommon StockSEC:0001209191-21-069790:0
Canonical exit: 13 Mar 2022 (T+90)
13 of 13 declarations
About Schulman Amy W
Amy W. Schulman is a Director at Elevance Health, Inc. and Alnylam Pharmaceuticals, Inc. She brings her expertise in strategy and governance to the board. Elevance Health is a healthcare services company, while Alnylam Pharmaceuticals focuses on developing innovative therapies. Ms. Schulman plays an active role in strategic direction and oversight of the companies' operations.
